Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML

15 May 2024

Abstract excerpt

ABSTRACT: Molecular measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Mast cells and histamine
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38749014
DOI: 10.1182/blood.2024024264

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AMLPMID 38749014Read ↗

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.Semantic proximity Read ↗

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapySemantic proximity Read ↗

Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual DiseaseSemantic proximity Read ↗

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profilingSemantic proximity Read ↗

Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.Semantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

The Black Hole: CAR T Cell Therapy in AMLSemantic proximity Read ↗

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.